Literature DB >> 22870105

Usefulness of desensitization protocol for a carboplatin hypersensitivity reaction during docetaxel-carboplatin therapy for recurrent ovarian cancer: Case report.

Tadahiro Shoji1, Eriko Takatori, Yoshitaka Kaido, Seisuke Kumagai, Satoshi Takeuchi, Akira Yoshizaki, Toru Sugiyama.   

Abstract

We report a case of recurrent ovarian cancer in which desensitization for a carboplatin hypersensitivity reaction proved useful. The patient was a 65-year-old woman who presented with a recurrence of stage IIIc ovarian cancer. The initial chemotherapy consisted of 6 courses of paclitaxel and carboplatin. Recurrence in the pelvis, splenic hilum and para-aortic lymph nodes was detected 19 months after the final day of treatment. The patient was treated with docetaxel-carboplatin therapy for the recurrence, but a Grade 3 hypersensitivity reaction to carboplatin was observed during the second course. Carboplatin desensitization was commenced with the third course and 6 courses were completed with no evidence of hypersensitivity reaction. The antitumor effect showed a complete response and the patient has had a disease-free survival thus far. Desensitization for patients diagnosed with a carboplatin hypersensitivity reaction appeared to be a key method of treatment for prolonging the survival time of patients with recurrent ovarian cancer.

Entities:  

Year:  2010        PMID: 22870105      PMCID: PMC3412508          DOI: 10.3892/ol.2010.192

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  20 in total

1.  Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study.

Authors:  A J González-Martín; E Calvo; I Bover; M J Rubio; A Arcusa; A Casado; B Ojeda; C Balañá; E Martínez; A Herrero; B Pardo; E Adrover; J Rifá; M J Godes; A Moyano; A Cervantes
Journal:  Ann Oncol       Date:  2005-04-07       Impact factor: 32.976

2.  Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center.

Authors:  M Markman; A Kennedy; K Webster; B Kulp; G Peterson; J Belinson
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

3.  Atypical presentations of carboplatin hypersensitivity reactions: characterization and management in patients with gynecologic malignancies.

Authors:  Jessica N McAlpine; Michael G Kelly; David M O'malley; Masoud Azodi; Karen Coombe; Peter E Schwartz; Thomas J Rutherford
Journal:  Gynecol Oncol       Date:  2006-05-02       Impact factor: 5.482

4.  Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses.

Authors:  Chyh-Woei Lee; Ursula A Matulonis; Mariana C Castells
Journal:  Gynecol Oncol       Date:  2005-07-27       Impact factor: 5.482

5.  Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital.

Authors:  Joanna R Schwartz; Christina Bandera; AnnMarie Bradley; Laurent Brard; Robert Legare; C O Granai; Don S Dizon
Journal:  Gynecol Oncol       Date:  2006-12-08       Impact factor: 5.482

6.  Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions.

Authors:  Chyh-Woei Lee; Ursula A Matulonis; Mariana C Castells
Journal:  Gynecol Oncol       Date:  2004-11       Impact factor: 5.482

Review 7.  Hypersensitivity reactions to chemotherapeutic drugs.

Authors:  Gillian M Shepherd
Journal:  Clin Rev Allergy Immunol       Date:  2003-06       Impact factor: 8.667

8.  Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions.

Authors:  Maurie Markman; Fred Hsieh; Kristine Zanotti; Kenneth Webster; Gertrude Peterson; Barbara Kulp; Ann Spicel; Jerome Belinson
Journal:  J Cancer Res Clin Oncol       Date:  2003-10-15       Impact factor: 4.553

9.  Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases.

Authors:  Mariana C Castells; Nichole M Tennant; David E Sloane; F Ida Hsu; Nora A Barrett; David I Hong; Tanya M Laidlaw; Henry J Legere; Samridhi N Nallamshetty; Ross I Palis; Jayanti J Rao; Suzanne T Berlin; Susana M Campos; Ursula A Matulonis
Journal:  J Allergy Clin Immunol       Date:  2008-05-27       Impact factor: 10.793

Review 10.  Management and preparedness for infusion and hypersensitivity reactions.

Authors:  Heinz-Josef Lenz
Journal:  Oncologist       Date:  2007-05
View more
  1 in total

1.  4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study.

Authors:  Naoto Takase; Koji Matsumoto; Takuma Onoe; Akihito Kitao; Maki Tanioka; Yoshitaka Kikukawa; Satoshi Yamaguchi; Kiyoshi Fujiwara; Shunichi Negoro
Journal:  Int J Clin Oncol       Date:  2014-07-18       Impact factor: 3.402

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.